Navidea Biopharmaceuticals Inc.
NAVB
NAVB was delisted on the 5th of October, 2023.
30 hedge funds and large institutions have $364K invested in Navidea Biopharmaceuticals Inc. in 2023 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, 10 reducing their positions, and 2 closing their positions.
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
7% more funds holding
Funds holding: 28 → 30 (+2)
3% less capital invested
Capital invested by funds: $375K → $364K (-$10.2K)
70% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 10
83% less call options, than puts
Call options by funds: $1K | Put options by funds: $6K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$50.5K |
| 2 |
Millennium Management
New York
|
+$37.6K |
| 3 |
ACM
Allred Capital Management
Dallas,
Texas
|
+$15.9K |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$292 |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$3 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$111K |
| 2 |
WAM
Warberg Asset Management
Winnetka,
Illinois
|
-$38.9K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$8.19K |
| 4 |
VF
Virtu Financial
New York
|
-$5.07K |
| 5 |
PP
PDS Planning
Dublin,
Ohio
|
-$2.22K |
NAVB Hedge Fund Activity: Q1 2023 in Review
30 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Navidea Biopharmaceuticals Inc. (NAVB) for Q1 2023, worth a combined $364K — down 2.7% from $375K a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new NAVB positions and 2 closed out — a net gain of 2 holders — while 3 added to existing stakes and 10 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $50.5K. The largest seller was Vanguard Group, cutting an estimated $111K.
- 30 institutional investors held Navidea Biopharmaceuticals Inc. (NAVB) as of Q1 2023, up from 28 in Q4 2022.
- Funds reported $364K of Navidea Biopharmaceuticals Inc. stock for Q1 2023, down 2.7% quarter-over-quarter.
- 4 funds opened new Navidea Biopharmaceuticals Inc. positions in Q1 2023 and 2 closed out, a net change of +2 holders.
- The largest Navidea Biopharmaceuticals Inc. buyer in Q1 2023 was Renaissance Technologies, an estimated $50.5K added.
- The largest Navidea Biopharmaceuticals Inc. seller in Q1 2023 was Vanguard Group, an estimated $111K sold.
Based on aggregated 13F filings for Q1 2023.